A Study of LY3502970 in Healthy Overweight and Obese Participants
Completed · Phase 1
Conditions studied: Healthy, Obese
In brief
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.
Key facts
- Study ID
- NCT05313802
- Run by
- Eli Lilly and Company
- People needed
- 72
- Starts
- 2022-05-26
- Expected to finish
- 2022-09-09
- Last updated by the study team
- 2026-05-26
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Participants with stable body weight for at least one month prior to randomization.
- Participants with body mass index (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²)
- Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential
You may not qualify if…
- Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs
- Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders
- Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %
Where it is running
- Qps-Mra, Llc — Miami, Florida, United States
- ICON Early Phase Services Lenexa Center — Lenexa, Kansas, United States
- ICON Early Phase Services — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.